[Humira has wide array of approved indications; newest is UC; UC indication could garner an additional $1B in Humira sales; survey of rheumatologists re FoB’s is bullish for ABT; ABT launches Absorb bioresorbable stent in 30 countries; AbbVie’s presumptive CEO misstated academic degrees.]
CORPORATE AND FINANCIAL
Planned split into two companies (Abbott and AbbVie) #msg-68255976 ABT announces split into two companies #msg-73944124 Analysts begin to calculate post-split valuation #msg-80008890 AbbVie’s presumptive misstated academic degrees
Finances, valuation, and track record #msg-77615146 2Q12 sales in emerging markets grow 14% YoY #msg-72254159 ABT hikes dividend for 40th consecutive year! #msg-77970916 Barron’s profiles Miles White, ABT’s CEO #msg-61658107 ABT is undervalued, says Barron’s (dated but still a good read) #msg-34774636 ABT’s M&A track record is second to none
THE NEW ABBOTT (current ABT minus AbbVie)
Branded generics and nutritionals businesses #msg-75216470New Abbott will be a consumer powerhouse #msg-74567343 New Abbott is beneficiary of The Global Demographic Tailwind (1) #msg-68255872 New Abbott is beneficiary of The Global Demographic Tailwind (2) #msg-61699995 Drug sales in emerging markets: $400B in 2020 (IMS) #msg-61960541Branded generics in emerging markets—connecting the dots #msg-62037218 More on branded generics (Forbes) #msg-50473238India’s fake drugs are a real problem #msg-50436738 Piramal acquisition (May 2010) #msg-50022514 Zydus Cadila acquisition (May 2010) #msg-41922225 Solvay acquisition (Sep 2009)
Diagnostics business #msg-66584680 FDA approves companion diagnostic for PFE’s Xalkori #msg-69394663 ABT, GSK ink deal for PLAME-antigen companion diagnostic
ABBVIE
Humira #msg-80043808Humira has wide array of approved indications (newest: UC) #msg-79013119 UC indication could garner additional $1B in Humira sales #msg-61383188Musings on threat to Humira from Tofacitinib (1) #msg-66970993 Musings on threat to Humira from Tofacitinib (2) #msg-79941294 Survey of rheumatologists re FoB’s is bullish for ABT
#msg-68743172 Data on Humira and Tofacitinib from ACR 2011 #msg-61989536 Antibodies against Humira are no big deal #msg-76327260 Roche study of Actemra vs Humira was biased #msg-74453479 A short history of Humira (Luke Timmerman) #msg-39417561 Size and segments of US market for RA
Kidney disease #msg-75234662ABT is amassing impressive portfolio in CKD #msg-64332248 Bardoxolone advances to phase-3 #msg-56946507 Phase-2b Bardoxolone data #msg-54747777 ABT licenses Reata’s Bardoxolone for CKD
Lipid franchise #msg-68828037 FDA requests phase-4 “outcomes” trial for TriLipix #msg-62207709 Capsule summary of TriCor ACCORD study #msg-62591674 Bearish musings on TriCor/TriLipix (Forbes) #msg-51992958 Does TriCor prevent diabetic retinopathy? #msg-63617748 NIH terminates Niaspan AIM-HIGH study #msg-28510348 Heart disease: Not about cholesterol? #msg-63656000 Once is happenstance, twice is coincidence, three times…
Elagolix program #msg-76277354 Elagolix starts phase-3 in endometriosis #msg-67040135 Elagolix starts phase-2 in uterine fibroids #msg-51386069 Economics of Elagolix partnership with NBIX #msg-51343858 ABT licenses NBIX’s Elagolix for endometriosis
HCV pipeline #msg-68216224 Purportedly unprecedented all-oral results in HCV (1) #msg-68216772 Purportedly unprecedented all-oral results in HCV (2)
Miscellaneous #msg-69825162ABT inks new $400M collaboration with Reata #msg-68221363 Pipeline overview from 10/21/11 webcast
#msg-68245312 Daclizumab succeeds in phase-2b #msg-50509176 Phase-3 Daclizumab trial in RRMS begins #msg-78092224 NIH study elucidates the MoA of Daclizumab in MS
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.